Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Jeppe Skov
  • Jens Juul Holst, Afd. for Endokrinologisk Forskning, Denmark
  • Jens Peter Goetze, Denmark
  • Jørgen Frøkiær
  • Jens Sandahl Christiansen, Denmark
The antihypertensive actions of glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to release of atrial natriuretic peptide (ANP) in mice. Whether a GLP-1 - ANP axis exists in humans is unknown. We examined twelve healthy young males in a randomised, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a two-hour native GLP-1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP-1 infusion increased the urinary sodium excretion markedly there were no significant changes in either proANP or proBNP concentrations. When GLP-1 infusion was stopped, sodium excretion rapidly declined. Since proANP concentration reflects ANP secretion our data cannot confirm the existence of a GLP-1 - ANP axis in humans. Especially the natriuretic effects of GLP-1 seem unlikely to be mediated exclusively via ANP.
Original languageEnglish
JournalEndocrine Connections
Volume3
Issue1
Pages (from-to)11-16
Number of pages7
ISSN2049-3614
DOIs
Publication statusPublished - 10 Dec 2013

See relations at Aarhus University Citationformats

ID: 66371058